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Inhibition of the CD4O-CD4Oligand pathway prevents murine
membranous glomerulonephritis
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Inhibition of the CD4O-CD4Oligand pathway prevents murine membra-
nous glomerulonephritis. Several forms of glomerulonephritis are induced
by antibodies against self or foreign antigens. Normal B lymphocyte
antibody production requires T cell costimulatory signals provided in part
by T cell surface expression of gp39/CD40ligand (CD4OL) that engages
the B cell receptor CD4O and induces B cell differentiation and immuno-
globulin class switching. We assessed the effect of disrupting the CD4OL-
CD4O costimulatory pathway, using a CD4O-Ig fusion protein, on the
development of membranous glomerulonephritis (MGN) in the mouse.
MGN is induced by mouse antibodies that recognize and bind to exog-
enously administered rabbit anti-mouse renal tubular brush border
(RbAMBB) IgG immobilized in the glomerular capillaiy wall. MGN did
not occur in nude mice, showing the need of the T cell function. C57B1/10
mice immunized with RbAMBB and treated with CD4O-Ig fusion protein
displayed a delayed autologous response and absence of MGN lesions,
while control fusion proteins failed to prevent the development of the
disease. These observations provide evidence that disruption of the
CD4O-CD4OL costimulatoiy pathway can prevent the development of
MGN by suppressing T cell-dependent antibody production.
Thymus-dependent humoral immune response requires an ar-
ticulate dialogue between T and B lymphocytes. T cells provide
stimulatory signals for B lymphocyte function and antibody pro-
duction partly through release of soluble cytokines [1] and partly
through cell surface receptors that recognize specific ligands on B
cells during cell-cell contact [2, 3]. The critical role of physical T
cell-B cell interaction in T cell-dependent antibody production
has been clearly demonstrated by the observation that combina-
tions of cytokines alone cannot replace physical contact in induc-
ing B cell proliferation and differentiation [4—7]. A variety of
other approaches have subsequently confirmed this view [3, 8, 9].
Cell-cell interaction is required for T cell antigen receptor recog-
nition of foreign peptides presented by B cell MHC class II
molecules. However, physical association also allows interaction
between several counter-receptors that regulate both T and B cell
responses [8, 9]. Some of these counter-receptors, including
LFA-1-ICAM-1, primarily facilitate intercellular adhesion,
whereas others, including CD4-MHC II, LFA3-CD2 and B7-
CD28 function as accessory signaling molecules that facilitate
mutual T cell-B cell stimulation by reducing the threshold of
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lymphocyte response to antigen or by transducing stimulatory
signals [9—11]. The receptor-ligand pair composed of the B
cell-associated receptor CD4O, and its T cell ligand CD4OL/gp39,
has recently been shown to play a key role in the regulation of T
cell-dependent antibody production [12—15].
CD4O is a 47 kDa cell surface glycoprotein expressed on most
mature and activated B cells [16], related to the TNF receptor
family of cell surface molecules [17]. Recently, a natural ligand of
CD4O, CD4OL!gp39, has been identified and found to be a type II
integral membrane protein, related to TNF and ligands of CD3O,
CD27, 4-1BB and Fas [18]. Cell surface expression of CD4OLI
gp39 in normal T cells is transient, occurring shortly after
activation and persisting for only a few hours [19—21]. In vitro,
both soluble CD4O-immunoglobulin fusion protein (CD4ORg, for
receptorgiobulin) and mAb to CD4OL/gp39 block T cell-depen-
dent B cell proliferation, Ig production and Ig-class switching [12,
20, 22]. Recombinant CD4OLIgp39 and mAb to CD4O, on the
other hand, induce these events in the presence of cytokines [20,
22—24]. Interestingly, B cells cultured with IL-4 and triggered by
anti-CD4O mAb produce IgE and IgG4, whereas in the presence
of IL-b, they preferentially synthesize IgG, IgA and 1gM [25, 26].
The physiologic importance of the CD4O-CD4OLIgp39 interaction
was discovered through the elucidation of the underlying defect in
a severe form of human immunodeficiency known as the hyper
1gM syndrome (HIM). HIM is characterized by overproduction of
1gM but absence of IgG, IgA and IgE, and is accompanied by
severe recurrent infections. Recent work has shown that T cells
from HIM patients express mutated CD4OL/gp39 that cannot
interact with CD4O on B cells [27—29]. B lymphocytes from these
patients are normal and display appropriate immunoglobulin class
switching upon stimulation with recombinant wild type CD4OLI
gp39 [28, 30].
Inappropriate antibody production against self-antigens as well
as normal antibody production against foreign antigens that fail to
be eliminated from the organism may lead to a variety of disease
states. Human idiopathic membranous glomerulonephritis
(MGN) is an antibody-mediated disease of unknown etiology that
may lead to renal failure. Morphologically, it is characterized by
glomerular subepithelial deposits of immune complexes, severe
basement membrane thickening, and little or no inflammatory
infiltrate [31]. Treatment is typically based on administration of
steroids and other immunosuppressive drugs with controversial
results [32].
The possibility to genetically manipulate cell surface receptors
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that mediate cell-cell interactions critical to immune responses
offers a potentially powerful means to selectively abrogate unde-
sirable T and/or B cell activity. In the present work, we have
explored the possibility to use soluble CD4O-Ig fusion protein
(CD4ORg) to prevent MON. Mice injected with purified rabbit-
anti-mouse pronase-digested renal tubular brush border IgG
(RbAMBB) develop glomerulonephritis that mimicks the mor-
phologic lesions of human MGN, providing a suitable animal
model of the disease [33]. We show that early administration of
CD4O-Ig fusion protein can prevent the development of MON in
the murine model. The ability of CD4ORg to block development
of renal lesions provides evidence for CD4O-CD40L/gp39 signal-
ing in MGN, and suggests that inhibition of this co-stimulatory
pathway may be useful in the treatment of antibody-mediated
disease.
Methods
Animals
Eight- to nine-week-old C57B1/10 and C57B1/6J nude (nu/nu)
mice were purchased from Jackson Laboratories (Bar Harbor,
ME, USA). Adult male New Zealand White rabbits were pur-
chased from Charles River Laboratories (Wilmington, MA,
USA).
Preparation of RbAMBB
Tubular brush border fraction was extracted from mouse kidney
cortices minced and sieved through a 90 stainless steel sieve,
according to the method of Assmann et al [33]. Sieved material
was centrifuged at 400 g for 10 minutes and the cell-pellet
discarded. The supernatant was then centrifuged at 78,000 g and
the resulting pellet washed three times with distilled water by
centrifugation at 78,000 g. The pellet, containing the tubular
fraction, was incubated at 37°C for two hours with 30 mg pronase
(Calbiochem-Behring Corp., La Jolla, CA, USA) in 60 ml of a
0.8% NaCl-0.02 M Tris HC1 buffer, pH 7.8, centrifuged at 100,000
g for one hour and lyophilized. Four rabbits were immunized with
20 mg of pronase-digested tubular brush border fraction in
complete Freund's adjuvant (Sigma Chemical Co., St. Louis, MO,
USA) and boosted four weeks later with 10 mg of the same
material in incomplete Freund's adjuvant (Sigma). Rabbits were
bled two weeks following the boost injection and the IgG fraction
from the pooled sera prepared as described [33]. IgG from normal
rabbit sera (NRb IgG) were used as a control.
Monoclonal antibodies and immunofluorescence microscopy
Fluorescein (FITC)-conjugated rat anti-mouse CD8a was from
Biosource (Camarillo, CA, USA); rat anti-mouse CD4 and rat
anti-mouse Thy 1.2 were from Pharmingen (San Diego, CA,
USA). Mouse anti-human Fe-specific IgG was from Sigma. Irrel-
evant IgG2 mAb L14 anti-simian virus 40 large T antigen (gift of
Dr. Ed Harlow, Massachusetts General Hospital, Charlestown,
MA, USA) was used as control and is referred to as IgG2 mAb.
FITC-conjugated goat anti-rabbit IgG, rabbit anti-mouse IgG and
rabbit anti-mouse C3 were purchased from Cappel Laboratories
(Downington, PA, USA). The goat anti-mouse IgG was absorbed
with rabbit IgG, and its specificity was confirmed by absence of
binding to kidneys of mice sacrified one day after injection of
rabbit anti-rat glomerular basement membrane antiserum [341,
while staining with FITC-goat anti-rabbit IgG showed marked
Table 1. Experimental design
Passive
Group N of mice
immunization
(day 0) Treatment
Days of
treatment
I 6 none none —
II 6 NRb IgG none —
III 10 RbAMBB PBS 0—40
IV 3 RbAMBB CD8mRg 0-40
V 6 RbAMBB IgG2 mAb 0-40
VI 7 RbAMBB CD4OmRg 0-40
VII 6 RbAMBB CD4OmRg 10-40
VIII 6 RbAMBB none —
Soluble fusion proteins (CD4OmRg and CD8mRg) and the irrelevant
IgG2 mAb were injected at the dose of 50 jg in 150 pJ of PBS on day 0
and evely other day subsequently. Group VIII was formed by C57B1/6J
(nu/nu) nude mice. All the animals were sacrificed 40 d after immuniza-
tion. Abbreviations are: NRb IgG, normal rabbit IgG; RbAMBB, rabbit
anti-mouse brush border IgG; CD8mRg, CD8 murine receptorglobulin;
CD4OmRg, CD4O murine receptorgiobulin (additional explanations are in
Methods).
linear deposits of rabbit IgG on the glomerular basement mem-
brane.
All animals were nephrectomized at autopsy and the tissue
frozen in liquid nitrogen. Cryostat-cut 5 j.m tissue sections were
mounted onto slides and stained with FITC conjugated antibody,
washed several times in PBS, and examined under an epifluores-
cence microscope. The intensity of staining was graded on a scale
from 0 to + -f+ + (0, absent; +, minimal and focal in amount and
extent; + +, moderate and focal; + + +, marked and diffuse;
+ + + +, very marked and diffuse). Semiquantitative photometric
immunofluorescence measurement of deposits of rabbit IgG
present in the glomeruli was performed on 300 randomly-selected
individual glomeruli at a magnification of 600X with a Nikon
photometer Model UP x 1 1A. Fluorescence intensity was ex-
pressed as the reciprocal of the exposure time.
Electron microscopy
Small fragments of renal cortex (3 mm3) were fixed in Kar-
novsky's paraformaldehyde-glutaraldehyde solution [35], post-
fixed in 1% osmium tetroxide and embedded in Epon 812. Thin
sections stained with uranyl acetate and lead citrate were studied
with a Hitachi electron microscope.
Flow cytomet!y
FACS analysis was performed on Ficoll-separated splenocytes
from all animals included in Groups h-Vu for Thyl.2, CD4 and
CD8 cell surface expression. In addition, the murine Th2 cell line
D10.G4.1 (ATCC, Rockville, MD, USA), unstimulated or stimu-
lated with 10 jLg/ml Concanavalin-A (Sigma) for six hours, and
unstimulated and 10 j.gIml Concanavalin A-stimulated, Ficoll-
separated, splenocytes from normal C57B1/10 mice, were incu-
bated with CD4ORg for 45 minutes at 4°C in PBS, followed by a
secondary FITC-conjugated goat-anti-mouse or goat anti-human
affinity purified antibody, washed and subjected to FACS analysis
(Becton-Dickinson, Mountainview, CA, USA). To avoid non-
specific Fe receptor-dependent binding, splenocytes were prein-
cubated for one hour at 4°C with 100 pg/ml purified mouse IgG
(Cappel Laboratories) in PBS, washed and then stained.
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Fig. 1. Binding of CD4ORg to murine lymphocytes. (A) Murine D10.G4.1 T cells stimulated with 10 tg/ml Concanavalin A for six hours, were incubated
with PBS (dotted line), 10 g/ml CD4OmRg (solid line) or 10 igfml CD8mRg (dashed line), followed by an FITC-labeled goat anti-mouse IgO. (B)
Unstimulated murine splenocytes were incubated with 10 pg/mI human IgG (broken line) or with 10 g/ml CD4OhRg (solid line), and splenocytes
stimulated with 10 g/ml Concanavalin A for six hours were incubated with CD4OhRg (dotted line) followed by an FITC-labeled goat anti-human IgG
that does not cross-react with mouse IgG.
Detection of mouse antibodies to rabbit IgG
The autologous antibody response phase of all animals in the
experimental groups was assessed by determination of serum
mouse anti-Rb IgG levels at days 0, 7, 21 and 40 after immuniza-
tion in an ELISA. Ninety-six-well microtiter plates were coated
with 1 jg/ml of purified rabbit IgG in PBS/0.02% sodium azide
overnight at 4°C. The plates were washed with PBS-0.05%
Tween-20 and incubated with PBS-2% skimmed milk for 30
minutes at room temperature (RT). After two washes with
PBS-0.05% Tween-20, serial 1:50 to 1:500 dilutions of serum
samples (100 j.dlwell) were added. Following an overnight incu-
bation at 4°C, the plates were washed and exposed for four hours
to alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma),
diluted 1:4000. After three washes with PBS-0.05% Tween-20,
p-nitrophenyl phosphate (Sigma) dissolved in a 0.1 M glycine/lO
mM MgCl2 solution, pH 9.4, was added. Following three hours of
incubation at RT, the colorimetric reaction was read at 405 nm in
an EL-310 Microplate Autoreader (Biotek Instruments Inc.,
Winooski, VT, USA).
Proteinuria and PBL counts
Proteinuria at day 40 after immunization was measured using a
Protein Assay Kit (Sigma) based on Peterson's modification of the
micro-Lowry method with a minimal sensitivity of 50 g!ml.
Samples of peripheral blood were collected in heparinized tubes
at the end of the treatment (day 40). Peripheral blood leukocytes
(PBL) were counted using a hemocytometer (Fisher Scientific
Co., Pittsburgh, PA, USA).
Development and production of soluble recombinant fusion
proteins
Soluble receptor globulins were developed by genetic fusion of
sequences encoding the extracellular region of murine CD4O to
genomic DNA sequences containing exons encoding the hinge,
CH2 and CH3 domains of murine IgG2 or human IgG1
(CD4OmRg and CD4OhRg, respectively) [36}. Synthetic oligonu-
cleotide primers complementary to the 5' and 3' extremities of the
nucleotide sequence encoding the extracellular domain of murine
CD4O were used to PCR-amplify mouse CD4O from cDNA
derived from the WEHI-231 murine B cell line (American Type
Culture Collection, Rockville, MD, USA) stimulated for four
hours with 5 jxg/ml pokeweed mitogen (Sigma). The forward and
reverse primers were designed to contain an XhoI and a BamHI
site, respectively, to facilitate in-frame ligation to Ig expression
vectors. Nucleotide sequences of the primers were:
Forward: 5' CAC GGG CTC GAG ATG GTG TCT TFG CCr
CGG CTG TGC GCG CTA TGG 3'
Reverse: 5' CGC GGG ATC CCG GGA CIT TAA ACC ACA
GAT GAC 3'
Thirty amplification cycles at 94°C/i minute/60°C!2 minutes!
72°C/3 minutes were performed using amplitaq polymerase (Per-
kin-Elmer) and buffers recommended by the vendor. Amplified
eDNA was subjected to XhoI/BamHI digestiOn and ligated to
X7ioI!BamHI-cut human IgG1 expression vector. For insertion
into the murine IgG2 expression vector, the CD4OhRg construct
was digested with MluI and BamHI and the insert ligated to
MluI/BamHI-cut murine IgG2 expression vector.
Plasmids containg sequences encoding CD4O receptorglobulins
bearing murine and human IgG Fc were introduced into COS
cells by electroporation at 250 V!960 F using a Biorad Gene
Pulser (Richmond, CA, USA). Serum-free supernatants were
collected five to seven days post-transfection and soluble fusion
proteins purified on protein A sepharose as previously described
[36]. A soluble CD8mRg fusion protein encoded by sequences
specific for the extracellular domain of human CD8, previously
shown to be non-reactive with murine tissues [37], and murine
IgG2 Fe was prepared using the same approach and served as a
control. Purified soluble fusion proteins were analyzed by SDS/
10% PAGE under reducing conditions. Gels were stained with
Coomassie blue.
A
Fluorescence intensity
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Table 2. Immunofluorescence findings
Groups
I II III IV V VI VII VIII
RbIgGa GPCW 0 0 ++++ ++++ ++++ 0 ++I+++ 0
M 0 0 0 0 0 0 0 0
BC 0 0 ++ ++ ++ ++ +I++ ++
T 0 0 +/-I-+ + + + + --
MIgG GPCW 0 0 ++++ ++++ ++++ 0 ++/+++ 0
M ++ ++ ++/+++ ++ ++ +-i-/+++ ++/++-i- +++
BC 0 0 +/0 +/0 0 +10 +10 +10
T 0 0 +10 +10 +10 0 +10 0
MC3 GPCW 0 0 + +f++ +/++ 0 +/0 0
M ++ ++ ++ ++ ++ ++ ++I+++ ++
BC ++1- +++ +++ +++ +++ +++ +++ +++
T +++ +++ +++ +++ +++ +++ +++ +++
Abbreviations are: Rb IgG, rabbit IgG; M IgG, mouse IgG; M C3, mouse C3; GPCW, glomerular peripheral capillary walls; M, mesangium; BC,
Bowman's capsule; T, tubular basement membrane.
Fig. 2. Glomerular immunofluorescence findings in a naive C57B1110 mouse, (A) Coarse deposits of mouse IgG in the mesangium. (B) Focal deposits
of mouse C3 in the mesangium, Bowman's capsule and tubular basement membranes. x400.
Induction of MGN and experimental design
C57B1/10 and C57B116J nude (nulnu) mice were surgically
mononephrectomized under sterile conditions and allowed to
fully recover for at least three weeks. On day 0 of the experiment,
all animals were immunized with a single injection of 7.5 mg
RbAMBB or NRb IgG in 300 1.d of PBS into the tail vein.
Experimental groups are summarized in Table 1. Mice in Groups
III to VI were injected every other day, from day 0 to day 40, with
50 g CD4OmRg, CD8mRg or IgG2 mAb in 150 tl PBS or with
150 .d PBS alone. Mice in Group VII were injected from day 10
to day 40 with 50 ig CD4OmRg in 150 d PBS every other day. All
of the mice in groups III to VII received the first ten injections i.v.
(tail vein), and the subsequent injection i.p. All animals were
sacrificed at day 40. In order to establish whether injections of
CD4OmRg modified the binding of RbAMBB to the kidneys,
additional mice, injected like mice in Groups II and VI, were
sacrified at day 1, and the immunofluorescence patterns were
compared.
Statistics
Statistical analysis, when applicable, was performed using Stat-
view IV software (Abacus Concepts, Berkeley, CA, USA) on a
Macintosh SE computer (Apple Computer, Inc., Cupertino, CA,
USA). Differences between groups were compared by one way
analysis of variance and unpaired t-test.
Results
Characterization of soluble recombinant murine CD4ORg
Murine CD4O extracellular domain-specific sequences were
amplified by PCR from WEHI 231 B cell cDNA and ligated to
genomic sequences containing murine IgG2 Fc or human IgG1
Fc exons [36]. Fusion proteins were recovered from COS cells
transfected with each of the constructs in a transient expression
system, and purified on protein A beads as described previously
[36]. Development of CD8mRg was performed by translocating
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Fig. 3. Immunofluorescence and electron microscopy of glomenili from a C57B1/10 mouse injected with RbAMBB and treated for 40 days with CD8mRg
(Group IJ'9. (A) Granular deposits of rabbit IgG in the peripheral glomerular capillary walls, in Bowman's capsule and in tubular basement membranes.
(B) Diffuse, granular deposits of mouse IgG in the peripheral glomerular capillary walls; coarse deposits are also present in the mesangium. (C) Granular
deposits of mouse C3 in the peripheral glomerular capillary walls; coarse deposits are also present in the mesangium and in Bowman's capsule. (D and
E) Electron micrographs showing deposits of foreign material between the basement membrane and the foot processes (arrow) or in the filtration slits
(arrowhead). (F) Electron micrograph showing lesions of the glomerular basement membrane similar to "spikes" of type 2 to 3 human MGN (small
asterisks), deposits of foreign material (arrow) and fusion of epithelial foot processes. A—C, X400; D—F, X40,000.
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Fig. 4. Circulating antibodies to Rb IgG detected by ELISA. At day 7 and
21, the titers of antibodies of Group VI mice were significantly lower than
those in Group III and V (*P < 0.05). The difference between the titers
in Group VIII and those in Groups III and V was always statistically
significant (lIP < 0.05). Naive mice had an average titer of 0.082 0.020,
which was considered as background in the assay. Symbols are: (—El—)
Group III, (—4--—) Group IV, (—U—) Group V, (—4-—) Group VI,
(—U—) Group VII, (—Li—) Group VIII.
the extracellular domain of human CD8 from an expression vector
containing human IgG1 Fe sequences [36] to the corresponding
plasmid containing murine IgG2 sequences. SDS/PAGE analysis
under reducing conditions showed that purified CD4OmRg,
CD4OhRg and CD8mRg migrated as single bands of 50, 45 and 55
kD, respectively (data not shown).
To determine ligand recognition by CD4OmRg, the murine
helper T cell line D10.G4.1 was subjected to a six hours stimula-
tion with 10 g/ml Concanavalin A, and tested for CD4OmRg
binding by flow cytometry. CD4OmRg specifically bound to stim-
ulated but not to unstimulated D10.G4.1 cells (Fig. 1A). Similarly,
CD4OhRg bound murine Concanavalin A-stimulated splenocytes
but reacted weakly with unstimulated splenocytes (Fig. 1B).
Development of MGN
Murine MGN was induced according to the method of Ass-
mann et al [33] by administering a single dose of 7.5 mg of
RbAMBB intravenously. To establish the chronology of the
lesions, 12 C57B1/10 mice injected with RbAMBB were subdi-
vided into four groups of three mice each that were sacrificed on
days 1, 10, 30 and 40 following injection. Kidney sections from
animals in each group were prepared and examined by immuno-
fluorescence. Specimens obtained at days 30 to 40 were also
studies by electron microscopy. On day 1, linear deposits of rabbit
IgG were seen in the peripheral glomerular capillary walls, in the
endothelium of peritubular capillaries and larger vessels and
along the brush border of proximal tubules (data not shown).
Linear, segmental deposits of mouse C3 were present in the
tubular basement membrane and in Bowman's capsule (see
Groups I and II). Deposits of mouse IgG were present in the
mesangium (see Groups I and II), but were not detectable in the
peripheral capillary walls. On day 10, the deposits of rabbit IgG in
the peripheral glomerular capillary walls were still linear, and
were associated with faint deposits of mouse IgG (data not
shown). C3 was present principally in the mesangium. The tubular
brush border was no longer stained. On days 30 and 40, diffuse
granular deposits of rabbit IgG, mouse IgG and mouse C3 were
visible in the peripheral glomerular capillary walls, corresponding
to dense deposits in the subepithelial part of the glomerular
basement membrane and "spikes" observed by electron micros-
copy (see Groups HI, IV and V). The tubular brush border
appeared normal.
Groups I and II
These groups were comprised of normal mice (Group I) and
mice injected with normal rabbit IgG (Group II). The experimen-
tal design is shown in Table 1. The results obtained by immuno-
fluorescence technique at day 40 are summarized in Table 2. In
Groups I and II, that provide negative controls for disease
development, coarse deposits of mouse IgG were present in the
mesangium (Fig. 2A). Linear segmental deposits of mouse C3
were localized in tubular basement membranes and in Bowman's
capsules (Fig. 2B). Some dense deposits were found by electron
microscopy in the mesangial matrices. These deposits were
present in almost all glomeruli and tubules. In contrast, the
peripheral glomerular capillary walls, the interstitium and both
small and large vessels were consistently normal. Renal deposits
of rabbit IgG were absent. Mouse anti-rabbit IgG were never
detectable in sera of Group I animals. Forty days after immuni-
zation, the average titer of mouse anti-rabbit IgG in the sera of
Group II mice was 0.72 0.14 OD. Proteinuria was 32 4.2
mg!dl and 30 8 mg/dl in Group I and II animals, respectively.
PBL count of Group II mice was 7.2 0.6 X 103/mm3 and
splenocyte FACS analysis showed 28.5 3.4% Thy 1.2k, 18.4
2.2% CD4, 7.5 0.2% CD8 cells.
Groups III, Wand V
Mice were injected with RbAMBB and treated with PBS
(Group III), CD8mRg (Group IV), or the irrelevant mouse
monoclonal antibody IgG2 (Group V). Some mice were injected
with RbAMBB and PBS, and sacrificed 1, 2 and three days
thereafter. On day 1 marked deposits of rabbit IgG were found in
glomerular capillary walls, in the brush border and tubular
basement membranes. Deposits of mouse C3 were absent. On
days 2 and 3 the deposition of rabbit IgG progressively decreased
in the glomerular capillary walls and in the brush border, while
granular deposits appeared in tubular basement membranes (not
shown). At day 40 mice of Groups III, IV and V developed diffuse
granular deposits of rabbit and mouse IgG in glomerular periph-
eral capillary walls, while murine C3 was detectable in only 30%
of the animals (Fig. 3A—C). Granular deposits of rabbit IgG, with
small amounts of mouse IgG, were present along the basement
membranes of proximal tubules and in Bowman's capsules. Elec-
tron microscopy revealed small dense deposits in the subepithelial
part of the glomerular basement membranes and "spikes" similar
to those seen in type 2 to 3 human MGN [31] (Fig. 3D—F).
Mesangial deposits were comparable to those observed in Group
I and II animals. Antibodies to rabbit IgG became detectable in
the serum of these mice at day 7 and reached a peak at day 21
(Fig. 4). Proteinuria was 33.5 9.4 mg/dl (Group III), 29.6 7.3
mg/dl (Group IV) and 27 4.6 mg/dl (Group V) and was
comparable to those in normal mice (Group I) and in mice
injected with normal RbIgG (Group II). This observation is
0 10 20
Time, days
I-
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Fig. 5. Immunofluorescence and electron microscopy in a C57B1110 mouse injected with RbAMBB and given CD4OmRg from day 0 to day 40. (A) Granular
deposits of rabbit IgG in the Bowman's capsule but not in glomerular peripheral capillary walls. (B) Deposits of mouse IgG in the mesangium, but not
in glomerular peripheral capillary walls. (C) Deposits of mouse C3 in the mesangium, in Bowman's capsule and in tubular basement membranes, but
not in glomerular peripheral capillary walls. (D) Electron micrograph showing normal glomerular capillary walls. A—C, >(400; D, X40,000.
consistent with that of Assmann et al [33]. The PBL count was 7.5
1.2 X 103/mm3, 6.8 1.1 X 103/mm3 and 7.0 0.9 X 103/mm3
in Group III, IV and V, respectively. FACS analysis showed the
following splenocyte phenotype: Group 111,29.2 4.4% Thy 1.2,
18.4 4.2% CD4, 8.3 1.0% CD8 cells; Group IV, 30.2
2.4% Thy 1.2k, 22.6 3.8% CD4, 8.0 0.7% CD8 cells;
Group V, 26.8 3.1% Thy 1.2k, 20.9 4.0% CD4, 6.9 1.2%
CD8 cells.
Group VI
Mice were immunized with RbAMBB and treated with
CD4OmRg from day 0 to day 40. In mice sacrified one day after
injection of RbAMBB and CD4OmRg the deposition of rabbit
IgG in glomerular capillary walls and tubular brush border was
unchanged, as compared to mice injected with RbAMBB and PBS
which were sacrified at the same interval of time (not shown). At
day 40 tissue examination by immunofluorescence and electron
microscopy revealed normal glomerular peripheral capillary walls
in all animals (Fig. 5A—D). The virtual absence of rabbit IgG,
compared to mice in Groups III to V, was confirmed by semi-
quantitative photometric analysis (Fig. 6). Granular deposits of
rabbit IgG were found in the basement membranes of proximal
tubules and in Bowman's capsules. Staining for mouse IgG and C3
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mice of Groups III, IV and V, were absent. Mesangial deposits of
mouse TgG and C3 did not differ from those seen in naive
C57B1/10 and control mice (Groups III, TV and V). Proteinuria
was 28.5 8.5 mg/dl. Circulating antibodies to rabbit IgG were
not detectable (Fig. 4).
Discussion
Fig. 6. Glomerular photometric analysis of the intensity of fluorescence
staining for Rb IgG at day 40, expressed as the rec:),rocal of the exposure
time(s). Values in Groups VI and VIII were significantly lower than those
in control Groups III, IV and V (*F < 0.05). Symbols are: () Group III,
(VA) Group IV, (ll.) Group V, () Group VI, (D) Group VII, () Group
VIII.
in the mesangium did not differ appreciably from that seen in mice
within Groups I to V. During the first three weeks following
immunization, mouse anti-rabbit TgG antibody levels were signif-
icantly lower than in Group ITT, TV and V animals (Fig. 4), but
rose to comparable titers thereafter. Proteinuria was 27.7 5.3
mg/dl PBL count was 7.1 0.9 x 103/mm3. Splenocyte phenotype
was comparable to that of Group III, TV and V animals, with 27.5
3.4% Thy 1.2, 18.4 3.6% CD4, and 7.5 2.2% CD8 cells.
Grnup VII
To determine the effect of CD4OmRg when administered
following disease onset, this group of animals received CD4OmRg,
their injections beginning on day 10 after RbAMBB immunization
when anti-RbIgG antibodies were detectable in serum. Two mice
within this group had significantly fewer immune deposits in the
peripheral glomerular capillary walls (Fig. 7A and B), whereas
glomerular deposits in the other four were comparable to those in
Group ITT, IV and V animals. Although the levels of circulating
mouse antibodies to rabbit TgG were lower than in Groups III, IV
and V, the difference was marginal (Fig. 4). Proteinuria (29.7
8.4 mg/dl), PBL counts and FACS analysis of splenocyte popula-
tions were comparable to those of normal mice.
Group VIII
Nude mice injected with RbAMBB comprised Group VITI. The
observations that RbAMBB-induced MGN appears to depend on
mouse anti-rabbit IgG production, and that it can be prevented by
interfering with T cell-dependent B cell stimulation along the
CD4O-CD4OLIgp39 axis, predict that production of this form of
MGN should not be possible in thymus-deficient animals. Accord-
ingly, we administered RbAMBB to a group of nude mice and
assessed any resulting glomerular lesions. Deposits of rabbit and
mouse IgG and C3 in the glomerular peripheral capillary walls
were minimal or absent (Fig. 7 C, D). By electron microscopy a
few gross irregularities were seen in the epithelial profile of the
glomerular basement membranes, but diffuse subepithelial depos-
its of foreign material and "spikes" comparable to those seen in
Several recent studies have shown that monoclonal antibodies
to, and soluble recombinant forms of, specific lymphoid cell
surface receptors that mediate cell-cell interaction and participate
in the regulation of lymphocyte response to antigenic stimulus,
can be used to manipulate the immune response and to control
inflammation. Thus, simultaneous administration of anti-ICAM-1
and anti-LFA-1 mAb has been observed to block graft rejection
[38] and rapidly progressive glomerulonephritis [39]. Soluble
CTLA-4 prolongs allograft [40] and xenograft [41] survival and
inhibits rapidly progressive glomerulonephritis [42]. Soluble L-
and P-selectin can respectively block peritoneal neutrophil efflux
[43] and prevent acute pulmonary inflammation [44]. An anti-
CD4OL mAb has been effective in preventing collagen-induced
murine arthritis [45]. Tn the present work we have shown that
soluble CD4ORg can prevent the development of MGN in the
mouse.
CD4ORg binds CD4OL/gp39 on the surface of activated T cells,
and may thereby prevent CD4OL/gp39-CD4O association during
cognate T cell-B cell interaction [12]. Since engagement of CD4O
by CD4OL/gp39 is required for B cell production of antigen-
specific IgG, it seems reasonable to suggest that inhibition of
CD4OL/gp39-CD4O interaction by CD4OmRg resulted in the delay
of mouse anti-Rb TgG antibody production in the present model.
The observed prevention of MGN by CD4OmRg was not due to
the Fc portion of the fusion protein, since CD8mRg and an
irrelevant isotype-matched murine mAb had no effect on antibody
deposition in the glomerular capillary walls. Whether binding of
CD4OmRg to activated T cells in vivo results in their opsonization
and lysis or only in prevention of CD4OIJgp39-CD4O interaction
has not been determined. However, the present results are
consistent with the notion that CD4OmRg induces selective func-
tional inhibition of T cell-B cell interaction without causing
leukopenia or even detectable T cell depletion.
MGN may be induced by antibodies binding to constitutive
antigens of glomerular visceral epithelial cells or to exogenous
antigens immobilized in the subepithelial region of the glomerular
basement membrane [46]. RbAMBB recognizes antigens ex-
pressed on the surface of murine glomerular endothelial and
visceral epithelial cells, including dipeptidyl peptidase IV [47] and
aminopeptidase A [48]. The resulting membrane antigen/rabbit
IgG complexes are shed between the epithelial cells and the
basement membrane [49]. Tn mice of Groups III, IV and V
progressive glomerular disease is induced by a strong and sus-
tained antibody response to rabbit TgG, which probably cross-links
immobilized immune complexes to the glomerular basement
membrane [50], resulting in progressive enlargement of the
complexes that appear as granular deposits in immunofluores-
cence and electron microscopy. Studies performed with cationic
antigens that become immobilized in glomeruli have shown that
cross-linking by antibody is a prerequisite for the persistence of
these antigens in the subepithelial region of the glomerular
basement membrane [51, 52]. We found that the early binding of
rabbit IgG to mouse kidneys was not modified by administration
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Fig. 7. Immunofluorescence findings in a C57B1/10 mouse injected with RbAMBB and given CD40mRg from day 10 to day 40 (A and B), and in a nude
mouse injected with RbAMBB (C and D). (A) Moderate granular deposits of rabbit IgG in glomerular peripheral capillary walls with marked deposits
in Bowman's capsule. (B) Minimal to moderate granular deposits of mouse IgG in glomerular peripheral capillary walls and in Bowman's capsule, with
coarse deposits in the mesangium. (C) Granular deposits of rabbit IgG in Bowman's capsule and in tubular basement membranes, but not in glomerular
peripheral capillary walls. (D) Deposits of mouse IgG in the mesangium, but not in glomerular peripheral capillary walls. x400.
of CD4OmRg. Thus our results indicate that the inhibition of the
autologous immune response was responsible for the clearance of
immune complexes by glomerular visceral epithelial cells [53], and
immune deposits did not develop in the peripheral glomerular
capillary walls. This interpretation is supported by the observation
that MGN did not occur in nude mice, which lack T cells and
cannot mount a T cell-dependent antibody response to rabbit IgG
[54].
In contrast, despite suppression of the autologous phase, gran-
ular deposits of rabbit IgG were found in the tubular basement
membranes and in the Bowman's capsules of mice treated with
CD4OmRg, as well as in control mice (Groups III, IV and V) and
in nude mice (Group VIII). We propose that formation of these
deposits does not require cross-linking by mouse IgG, and that
they are formed by rabbit IgG and plasma membrane antigens of
brush border and basolateral membranes. This hypothesis is in
agreement with our previous observations of immune deposits in
the basolateral compartments of rabbits [55] and rats [56] injected
intravenously with anti-brush border antibodies. The immune
deposits in Bowman's capsules are probably formed by complexes
of rabbit IgG and plasma membrane antigens shed by glomeruli
and reabsorbed by the tubules. Regardless of the nature of the
immune deposits, their rapid removal from the peripheral gb-
merular capillary walls in mice treated with CD4OmRg contrasts
with their persistance in tubular basement membranes and Bow-
man's capsules, and suggests different mechanisms of clearance in
various parts of the nephron.
While CD4OmRg has been observed to be a potent inhibitor of
MGN development in the murine model, its effectiveness in
reversing established disease was less obvious. Two out of six
animals did show a marked reduction in rabbit and murine IgG
deposits but only a minimal reduction was seen in four others.
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This is most likely a reflection of transient CD4OLIgp39 expres-
sion on activated T cells, suggesting that timing of CD4OmRg
administration is of paramount importance. If cognate T cell-B
cell interaction, and more specifically, mutual CD4OL/gp39-CD4O
triggering, has already occurred, CD4ORg may no longer be able
to prevent high affinity antibody production. Thus, effectiveness,
at least in the present model, appears maximal when CD4OmRg
and antigen are administered simultaneously. Interestingly, the
autologous response phase is inhibited transiently by CD4OmRg
treatment, and anti-Rb IgG levels in treated animals at 40 days are
similar to those of untreated controls. Additional support to this
view is provided by a recent study on the effect of a soluble CD4O
on antibody response in vivo [57]. Possible explanations for the
transient inhibitory effect include potential alternative routes for
regulation of antibody production that might bypass the CD4O-
CD4OLJgp39 axis, and production of antibodies against an immu-
nogenic CD4OmRg epitope, that over time inactivate the fusion
protein. Importantly, the presence of mouse anti-Rb IgG antibod-
ies, even in high titers at day 40, can no longer induce MGN, since
rabbit IgG has been removed by local cellular mechanisms.
The present study provides direct evidence that timely admin-
istration of CD4OmRg can efficiently inhibit antibody-mediated
glomerular disease. Maximal effectiveness of CD4OmRg appears
to occur during a narrow window of early immune response,
corresponding to cell surface expression of CD4OL/gp39 [13, 14,
58]. CD4OmRg may therefore provide a valuable reagent in
studying the pathogenesis of immune-mediated renal disease.
Because of the importance of the time of administration with
respect to the disease process, as illustrated by the present model,
the effectiveness of CD4ORg in clinical situations may depend in
part on diagnostic approaches that are able to uncover early
phases of disease activity and exacerbation.
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